GlassScriptPhysician profile
Joseph L Gorz
NPI 1306286893
$4,836.36
in general payments reported to CMS, 2019-2025
32 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $74.32 · 2021: $520 · 2022: $361 · 2023: $1,116 · 2024: $1,079 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Travel and Lodging: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.47 |
| Travel and Lodging | $368.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $807.76 | 2023-2025 | Imfinzi, Breztri, Airsupra |
| Lilly USA, LLC | $594.01 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Biofrontera INC. | $471.91 | 2019 | |
| Pfizer INC. | $349.53 | 2023-2025 | |
| Novo Nordisk INC | $313.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $241.30 | 2021-2025 | |
| Alkermes, INC. | $213.84 | 2019-2024 | Vivitrol, Vivitrol |
| Amgen INC. | $183.58 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $182.14 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kerecis Limited | $126.16 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Exact Sciences Corporation | $123.26 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $111.29 | 2023-2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $108.22 | 2024-2025 | Zenpep |
| Shield Therapeutics INC | $99.95 | 2023-2024 | Accrufer |
| Cranial Technologies, INC | $93.55 | 2022-2024 | Doc Band |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $92.19 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $77.95 | 2021 | |
| Nestle Healthcare Nutrition INC. | $77.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.84 | 2024-2025 | |
| Corcept Therapeutics | $60.13 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $59.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.69 | 2023-2024 | Eliquis |
| Astellas Pharma US INC | $50.28 | 2021-2024 | Veozah |
| Allergan, INC. | $43.17 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.79 | 2024 | Trintellix |
| Seqirus USA INC | $34.14 | 2025 | Flucelvax, Fluad |
| Hologic Sales and Service, LLC | $33.68 | 2023 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $28.81 | 2024 | Dexcom G6 Transmitter |
| Medicomp INC | $28.35 | 2021-2022 | |
| Baxter Healthcare | $27.89 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $23.28 | 2022 | |
| Dynavax Technologies Corporation | $15.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gorz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.